HIMA/ACCJ Device Proposal To Build On U.S./Japan May 15 Joint Statement
This article was originally published in The Gray Sheet
Officials from the American Chamber of Commerce in Japan will hold informal talks with officials of Japan's Ministry of Health and Welfare the first week in June to unveil a U.S. industry-crafted proposal to revise the "functional categories" section of MHW's "by function" device reimbursement system.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.